North America Musculoskeletal (MSK) Disease Management Market - Industry Trends Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION 21

• 1.1 OBJECTIVES OF THE STUDY 21
• 1.2 MARKET DEFINITION 21
• 1.3 OVERVIEW OF THE NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET 21
• 1.4 CURRENCY AND PRICING 24
• 1.5 LIMITATION 24
• 1.6 MARKETS COVERED 24

2 MARKET SEGMENTATION 30

• 2.1 MARKETS COVERED 30
• 2.2 GEOGRAPHIC SCOPE 31
• 2.3 YEARS CONSIDERED FOR THE STUDY 32
• 2.4 CURRENCY AND PRICING 32
• 2.5 RESEARCH METHODOLOGY 33
• 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
• 2.7 MULTIVARIATE MODELLING 37
• 2.8 TYPE SEGMENT LIFELINE CURVE 37
• 2.9 DBMR MARKET POSITION GRID 38
• 2.10 VENDOR SHARE ANALYSIS 40
• 2.11 MARKET APPLICATION COVERAGE GRID 41
• 2.12 THE CATEGORY VS TIME GRID 42
• 2.13 SECONDARY SOURCES 43
• 2.14 ASSUMPTIONS 43

3 EXECUTIVE SUMMARY 44

4 PREMIUM INSIGHTS 47

• 4.1 PESTEL ANALYSIS 48
• 4.2 PORTER'S FIVE FORCE 49
• 4.3 KEY STRATEGIC INITIATIVES 50
• 4.4 EMERGING TREND ANALYSIS OF DIGITAL REHABILITATION AND DIGITAL PHYSIOTHERAPY IN THE NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET 52
  • 4.4.1 DIGITAL REHABILITATION 52
  • 4.4.2 DIGITAL PHYSIOTHERAPY 52

5 EPIDEMIOLOGY 54

• 5.1 U.S. 54
• 5.2 CANADA 55
• 5.3 MEXICO 56

6 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: REGULATIONS 68

7 MARKET OVERVIEW 72

• 7.1 DRIVERS 74
  • 7.1.1 TECHNOLOGICAL ADVANCES IN THE DIAGNOSIS OF MUSCULOSKELETAL DISORDERS (MSDS) 74
  • 7.1.2 RISING AWARENESS ABOUT MUSCULOSKELETAL DISORDERS (MSDS) 74
  • 7.1.3 GROWING PREVALENCE OF RHEUMATOID ARTHRITIS (RA) 75
  • 7.1.4 INCREASING CASES OF BONE FRACTURES 75
• 7.2 RESTRAINTS 76
  • 7.2.1 HIGH COST OF DIAGNOSIS AND TREATMENT OF ORTHOPEDIC DISEASES 76
  • 7.2.2 RISE IN USE OF HEAVY-DUTY DRUGS IN TREATING MUSCULOSKELETAL (MSK) PAIN 77
• 7.3 OPPORTUNITIES 77
  • 7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 77
  • 7.3.2 USE OF TELEMEDICINE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 78
  • 7.3.3 INCREASED USE OF MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 79
  • 7.3.4 USE OF HOME HEALTHCARE FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 79
• 7.4 CHALLENGES 80
  • 7.4.1 CHALLENGES FACED BY PHYSICIANS WHILE TREATING ATHLETES WITH MUSCULOSKELETAL (MSK) DISEASES 80
  • 7.4.2 STRICT REGULATORY GUIDELINES FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT 80

8 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE 81

• 8.1 OVERVIEW 82
• 8.2 DIGITAL BIOFEEDBACK SYSTEM 86
• 8.3 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 87
  • 8.3.1 IOS-SYSTEMS 88
  • 8.3.2 ANDROID-SYSTEMS 88
  • 8.3.3 OTHER SYSTEMS 88
• 8.4 SOLUTIONS 88
  • 8.4.1 DIRECT SUPPORT 89
    • 8.4.1.1 MULTIMODAL PAIN THERAPY 90
    • 8.4.1.2 ONSITE PERSONALIZED THERAPY 90
    • 8.4.1.3 SOLUTIONS TO REDUCE INJURIES 90
    • 8.4.1.4 MIND-BODY CONNECTION IMPROVEMENT 90
    • 8.4.1.5 EARLY PREVENTION AND INTERVENTION 90
    • 8.4.1.6 PREVENTION, RECOVERY AND EDUCATION 90
    • 8.4.1.7 PERSONALIZED PAIN RECOVERY 90
    • 8.4.1.8 SENSOR-GUIDED EXERCISE THERAPY 90
    • 8.4.1.9 TRAINING OF EDUCATION SKILLS 90
    • 8.4.1.10 SELF-TRACKING OF PAIN EPISODES 90
    • 8.4.1.11 RELAXATION TECHNIQUES 91
    • 8.4.1.12 POST-OPERATIVE PAIN TRACKING 91
      • 8.4.1.12.1 REAL-TIME MONITORING 91
      • 8.4.1.12.2 SYMPTOM MANAGEMENT 91
    • 8.4.1.13 OTHERS 91
  • 8.4.2 PROGRESS TRACKING 91
  • 8.4.3 OTHERS 91
• 8.5 OTHERS 92

9 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY 93

• 9.1 OVERVIEW 94
• 9.2 PRECISION MOTION TECHNOLOGY 98
• 9.3 COMPUTER MOTION TECHNOLOGY 98
• 9.4 OTHER TECHNOLOGIES 98

10 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE 99

• 10.1 OVERVIEW 100
• 10.2 PHONE 104
  • 10.2.1 DIGITAL BIOFEEDBACK SYSTEM 105
  • 10.2.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 105
  • 10.2.3 THERAPIES 105
  • 10.2.4 OTHERS 105
• 10.3 TABLET 105
  • 10.3.1 DIGITAL BIOFEEDBACK SYSTEM 107
  • 10.3.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 107
  • 10.3.3 THERAPIES 107
  • 10.3.4 OTHERS 107
• 10.4 COMPUTER 107
  • 10.4.1 DIGITAL BIOFEEDBACK SYSTEM 108
  • 10.4.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) 108
  • 10.4.3 THERAPIES 108
  • 10.4.4 OTHERS 108
• 10.5 OTHERS 109

11 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY 110

• 11.1 OVERVIEW 111
• 11.2 VIRTUAL THERAPY 115
  • 11.2.1 INTERNET BASED 116
  • 11.2.2 TELEPHONE BASED 116
  • 11.2.3 MOBILE PHONE APPLICATION 116
  • 11.2.4 INTERNET BASED WITH TELEPHONE SUPPORT 116
  • 11.2.5 INTERACTIVE VOICE RESPONSE 117
  • 11.2.6 VIDEO TELECONFERENCING 117
  • 11.2.7 MOBILE PHONE APPLICATION WITH TELEPHONE SUPPORT 117
  • 11.2.8 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT 117
  • 11.2.9 INTERNET BASED WITH VIDEO CONFERENCING 117
  • 11.2.10 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT AND INTERNET BASED 117
  • 11.2.11 OTHERS 117
• 11.3 IN-PERSON THERAPY 117
• 11.4 CUSTOMIZED/ PERSONALIZED THERAPY 118
• 11.5 OTHERS 119

12 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION 120

• 12.1 OVERVIEW 121
• 12.2 PRE-SURGERY APPLICATION 125
  • 12.2.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY 126
  • 12.2.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY 126
  • 12.2.3 LATERAL LUMBAR INTERBODY FUSION SURGERY 126
  • 12.2.4 INTERNET BASED WITH TELEPHONE SUPPORT 126
  • 12.2.5 MINIMALLY INVASIVE SPINE SURGERY 126
  • 12.2.6 MOTION PRESERVING SPINE SURGERY 126
  • 12.2.7 POSTERIOR CERVICAL FUSION SURGERY 126
  • 12.2.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY 126
  • 12.2.9 SACROILIAC JOINT FUSION SURGERY 126
  • 12.2.10 SCOLIOSIS CORRECTION SURGERY 127
  • 12.2.11 VERTEBRAL AUGMENTATION SURGERY 127
  • 12.2.12 FRACTURE FIXATION SURGERY 127
  • 12.2.13 HIP SURGERY 127
    • 12.2.13.1 TOTAL HIP REPLACEMENT 127
    • 12.2.13.2 PARTIAL HIP REPLACEMENT 127
    • 12.2.13.3 HIP RESURFACING 127
    • 12.2.13.4 OTHERS 128
  • 12.2.14 KNEE SURGERY 128
    • 12.2.14.1 TOTAL KNEE REPLACEMENT 128
    • 12.2.14.2 PARTIAL KNEE REPLACEMENT 128
    • 12.2.14.3 MISS FUSION 128
    • 12.2.14.4 OTHERS 128
• 12.3 POST-SURGERY APPLICATION 129
  • 12.3.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY 130
  • 12.3.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY 130
  • 12.3.3 LATERAL LUMBAR INTERBODY FUSION SURGERY 130
  • 12.3.4 INTERNET BASED WITH TELEPHONE SUPPORT 130
  • 12.3.5 MINIMALLY INVASIVE SPINE SURGERY 130
  • 12.3.6 MOTION PRESERVING SPINE SURGERY 130
  • 12.3.7 POSTERIOR CERVICAL FUSION SURGERY 130
  • 12.3.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY 130
  • 12.3.9 SACROILIAC JOINT FUSION SURGERY 130
  • 12.3.10 SCOLIOSIS CORRECTION SURGERY 130
  • 12.3.11 VERTEBRAL AUGMENTATION SURGERY 131
  • 12.3.12 FRACTURE FIXATION SURGERY 131
  • 12.3.13 HIP SURGERY 131
    • 12.3.13.1 TOTAL HIP REPLACEMENT 131
    • 12.3.13.2 PARTIAL HIP REPLACEMENT 131
    • 12.3.13.3 HIP RESURFACING 131
    • 12.3.13.4 OTHERS 132
  • 12.3.14 KNEE SURGERY 132
    • 12.3.14.1 TOTAL KNEE REPLACEMENT 132
    • 12.3.14.2 PARTIAL KNEE REPLACEMENT 132
    • 12.3.14.3 MISS FUSION 132
    • 12.3.14.4 OTHERS 132

13 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION 133

• 13.1 OVERVIEW 134
• 13.2 PEDIATRICS 138
  • 13.2.1 MALE 138
  • 13.2.2 FEMALE 138
• 13.3 ADULTS 138
  • 13.3.1 MALE 139
  • 13.3.2 FEMALE 139
• 13.4 GERIATRIC 139
  • 13.4.1 MALE 140
  • 13.4.2 FEMALE 140

14 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER 141

• 14.1 OVERVIEW 142
• 14.2 HOSPITALS & CLINICS 145
  • 14.2.1 MULTIPLE 145
  • 14.2.2 PHYSICAL THERAPIST 145
  • 14.2.3 NURSE 145
  • 14.2.4 HEALTH COACH 146
  • 14.2.5 OTHERS 146
• 14.3 NURSING HOMES 146
  • 14.3.1 MULTIPLE 147
  • 14.3.2 PHYSICAL THERAPIST 147
  • 14.3.3 NURSE 147
  • 14.3.4 HEALTH COACH 147
  • 14.3.5 OTHERS 147
• 14.4 HEALTH CENTERS 147
  • 14.4.1 MULTIPLE 148
  • 14.4.2 PHYSICAL THERAPIST 148
  • 14.4.3 NURSE 148
  • 14.4.4 HEALTH COACH 148
  • 14.4.5 OTHERS 148
• 14.5 REHABILITATION CENTERS 148
  • 14.5.1 MULTIPLE 149
  • 14.5.2 PHYSICAL THERAPIST 149
  • 14.5.3 NURSE 149
  • 14.5.4 HEALTH COACH 149
  • 14.5.5 OTHERS 150
• 14.6 VIRTUAL/HOME HEALTH CARE SETTINGS 150
  • 14.6.1 MULTIPLE 151
  • 14.6.2 PHYSICAL THERAPIST 151
  • 14.6.3 NURSE 151
  • 14.6.4 HEALTH COACH 151
  • 14.6.5 OTHERS 151
• 14.7 OTHERS 151

15 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION 152

• 15.1 OVERVIEW 153
  • 15.1.1 U.S. 158
  • 15.1.2 CANADA 170
  • 15.1.3 MEXICO 181

16 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY LANDSCAPE 192

• 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 192

17 SWOT ANALYSIS 193

18 COMPANY PROFILE 194

• 18.1 HINGE HEALTH, INC 194
  • 18.1.1 COMPANY SNAPSHOT 194
  • 18.1.2 PRODUCT PORTFOLIO 194
  • 18.1.3 RECENT DEVELOPMENTS 194
• 18.2 SWORD HEALTH, INC 196
  • 18.2.1 COMPANY SNAPSHOT 196
  • 18.2.2 PRODUCT PORTFOLIO 196
  • 18.2.3 RECENT DEVELOPMENT 196
• 18.3 OMADA HEALTHA INC. 197
  • 18.3.1 COMPANY SNAPSHOT 197
  • 18.3.2 PRODUCT PORTFOLIO 197
  • 18.3.3 RECENT DEVELOPMENT 197
• 18.4 KAIA HEALTH 198
  • 18.4.1 COMPANY SNAPSHOT 198
  • 18.4.2 PRODUCT PORTFOLIO 198
  • 18.4.3 RECENT DEVELOPMENTS 199
• 18.5 WELLNESS COACHES USA, LLC. 200
  • 18.5.1 COMPANY SNAPSHOT 200
  • 18.5.2 PRODUCT PORTFOLIO 200
  • 18.5.3 RECENT DEVELOPMENT 200
• 18.6 AIRROSTI REHAB CENTER, LLC 202
  • 18.6.1 COMPANY SNAPSHOT 202
  • 18.6.2 PRODUCT PORTFOLIO 202
  • 18.6.3 RECENT DEVELOPMENTS 202
• 18.7 DARIOHEALTH CORP. (2021) 204
  • 18.7.1 COMPANY SNAPSHOT 204
  • 18.7.2 REVENUE ANALYSIS 204
  • 18.7.3 PRODUCT PORTFOLIO 205
  • 18.7.4 RECENT DEVELOPMENTS 205

• 18.8 INCLUDEHEALTH 206
  • 18.8.1 COMPANY SNAPSHOT 206
  • 18.8.2 PRODUCT PORTFOLIO 206
  • 18.8.3 RECENT DEVELOPMENTS 206
• 18.9 IMC 207
  • 18.9.1 COMPANY SNAPSHOT 207
  • 18.9.2 PRODUCT PORTFOLIO 207
  • 18.9.3 RECENT DEVELOPMENT 207
• 18.10 KIIO 208
  • 18.10.1 COMPANY SNAPSHOT 208
  • 18.10.2 PRODUCT PORTFOLIO 208
  • 18.10.3 RECENT DEVELOPMENT 208
• 18.11 LIMBER HEALTH, INC. 210
  • 18.11.1 COMPANY SNAPSHOT 210
  • 18.11.2 PRODUCT PORTFOLIO 210
  • 18.11.3 RECENT DEVELOPMENT 210
• 18.12 MOVEMENT RX 211
  • 18.12.1 COMPANY SNAPSHOT 211
  • 18.12.2 PRODUCT PORTFOLIO 211
  • 18.12.3 RECENT DEVELOPMENT 211
• 18.13 PHZIO 212
  • 18.13.1 COMPANY SNAPSHOT 212
  • 18.13.2 PRODUCT PORTFOLIO 212
  • 18.13.3 RECENT DEVELOPMENT 212
• 18.14 RECOVERYONE 213
  • 18.14.1 COMPANY SNAPSHOT 213
  • 18.14.2 PRODUCT PORTFOLIO 213
  • 18.14.3 RECENT DEVELOPMENT 213
• 18.15 SPARTA SCIENCE 214
  • 18.15.1 COMPANY SNAPSHOT 214
  • 18.15.2 PRODUCT PORTFOLIO 214
  • 18.15.3 RECENT DEVELOPMENTS 214
• 18.16 SPRITE HEALTH 216
  • 18.16.1 COMPANY SNAPSHOT 216
  • 18.16.2 PRODUCT PORTFOLIO 216
  • 18.16.3 RECENT DEVELOPMENTS 216
• 18.17 SIMPLETHERAPY, INC. 217
  • 18.17.1 COMPANY SNAPSHOT 217
  • 18.17.2 PRODUCT PORTFOLIO 217
  • 18.17.3 RECENT DEVELOPMENT 217

19 QUESTIONNAIRE 218

20 RELATED REPORTS 222

LIST OF TABLES

• TABLE 1 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 85
• TABLE 2 NORTH AMERICA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 87
• TABLE 3 NORTH AMERICA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 89
• TABLE 4 NORTH AMERICA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION) 89
• TABLE 5 NORTH AMERICA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 91
• TABLE 6 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 97
• TABLE 7 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 103
• TABLE 8 NORTH AMERICA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 105
• TABLE 9 NORTH AMERICA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 106
• TABLE 10 NORTH AMERICA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 108
• TABLE 11 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 114
• TABLE 12 NORTH AMERICA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 116
• TABLE 13 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 124
• TABLE 14 NORTH AMERICA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 125
• TABLE 15 NORTH AMERICA HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 127
• TABLE 16 NORTH AMERICA KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 128
• TABLE 17 NORTH AMERICA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
• TABLE 18 NORTH AMERICA HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 131
• TABLE 19 NORTH AMERICA KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 132
• TABLE 20 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 137
• TABLE 21 NORTH AMERICA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 138
• TABLE 22 NORTH AMERICA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 139
• TABLE 23 NORTH AMERICA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 139
• TABLE 24 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION) 144
• TABLE 25 NORTH AMERICA HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 145
• TABLE 26 NORTH AMERICA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 146
• TABLE 27 NORTH AMERICA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 148
• TABLE 28 NORTH AMERICA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 149
• TABLE 29 NORTH AMERICA VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 150
• TABLE 30 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 153
• TABLE 31 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
• TABLE 32 U.S. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS) 158
• TABLE 33 U.S. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD) 158
• TABLE 34 U.S. MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 158
• TABLE 35 U.S. SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
• TABLE 36 U.S. DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION) 159
• TABLE 37 U.S. POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
• TABLE 38 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 160
• TABLE 39 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 160
• TABLE 40 U.S. PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 160
• TABLE 41 U.S. TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 161
• TABLE 42 U.S. COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 161
• TABLE 43 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 161
• TABLE 44 U.S. VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 162
• TABLE 45 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 162
• TABLE 46 U.S. PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 163
• TABLE 47 U.S. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 164
• TABLE 48 U.S. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 164
• TABLE 49 U.S. POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 165
• TABLE 50 U.S. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
• TABLE 51 U.S. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
• TABLE 52 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 166
• TABLE 53 U.S. PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 166
• TABLE 54 U.S. ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 167
• TABLE 55 U.S. GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 167
• TABLE 56 U.S. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION) 167
• TABLE 57 U.S. HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 168
• TABLE 58 U.S. NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 168
• TABLE 59 U.S. HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 168
• TABLE 60 U.S. REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 169
• TABLE 61 U.S. VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 169
• TABLE 62 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
• TABLE 63 CANADA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS) 170
• TABLE 64 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
• TABLE 65 CANADA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 170
• TABLE 66 CANADA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION) 171
• TABLE 67 CANADA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 171
• TABLE 68 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 171
• TABLE 69 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 172
• TABLE 70 CANADA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 172
• TABLE 71 CANADA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 172
• TABLE 72 CANADA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 173
• TABLE 73 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 173
• TABLE 74 CANADA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 174
• TABLE 75 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
• TABLE 76 CANADA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
• TABLE 77 CANADA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 175
• TABLE 78 CANADA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
• TABLE 79 CANADA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 176
• TABLE 80 CANADA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 177
• TABLE 81 CANADA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 177
• TABLE 82 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 177
• TABLE 83 CANADA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 177
• TABLE 84 CANADA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 178
• TABLE 85 CANADA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 178
• TABLE 86 CANADA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION) 178
• TABLE 87 CANADA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 179
• TABLE 88 CANADA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 179
• TABLE 89 CANADA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 179
• TABLE 90 CANADA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 180
• TABLE 91 CANADA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 180
• TABLE 92 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 181
• TABLE 93 MEXICO DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS) 181
• TABLE 94 MEXICO DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD) 181
• TABLE 95 MEXICO MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 181
• TABLE 96 MEXICO SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
• TABLE 97 MEXICO DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION) 182
• TABLE 98 MEXICO POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION) 182
• TABLE 99 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 183
• TABLE 100 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 183
• TABLE 101 MEXICO PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 183
• TABLE 102 MEXICO TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 184
• TABLE 103 MEXICO COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION) 184
• TABLE 104 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 184
• TABLE 105 MEXICO VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION) 185
• TABLE 106 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 185
• TABLE 107 MEXICO PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 186
• TABLE 108 MEXICO HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 186
• TABLE 109 MEXICO KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 187
• TABLE 110 MEXICO POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 187
• TABLE 111 MEXICO HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 188
• TABLE 112 MEXICO KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 188
• TABLE 113 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 188
• TABLE 114 MEXICO PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 188
• TABLE 115 MEXICO ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 189
• TABLE 116 MEXICO GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION) 189
• TABLE 117 MEXICO MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION) 189
• TABLE 118 MEXICO HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 189
• TABLE 119 MEXICO NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 190
• TABLE 120 MEXICO HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 190
• TABLE 121 MEXICO REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 190
• TABLE 122 MEXICO VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION) 191

LIST OF FIGURES

• FIGURE 1 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SEGMENTATION 30
• FIGURE 2 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: GEOGRAPHIC SCOPE 31
• FIGURE 3 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DATA TRIANGULATION 33
• FIGURE 4 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT 34
• FIGURE 5 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BOTTOM-UP APPROACH 35
• FIGURE 6 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: TOP-DOWN APPROACH 35
• FIGURE 7 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: INTERVIEWS BY REGION AND DESIGNATION 36
• FIGURE 8 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DBMR MARKET POSITION GRID 38
• FIGURE 9 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: VENDOR SHARE ANALYSIS 40
• FIGURE 10 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: APPLICATION COVERAGE GRID 41
• FIGURE 11 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: THE CATEGORY VS TIME GRID 42
• FIGURE 12 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET SEGMENTATION 46
• FIGURE 13 RISE IN AWARENESS ABOUT MUSCULOSKELETAL (MSK) DISEASES, GROWING PREVALENCE OF RHEUMATOID ARTHRITIS, TECHNOLOGICAL ADVANCEMENTS IN MUSCULOSKELETAL (MSK) DISEASES, AND STRATEGIC INITIATIVES BY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MARKET GROWTH FOR NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 47
• FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN 2023 & 2030 47
• FIGURE 15 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET : EPIDEMIOLOGY 57
• FIGURE 16 PREVALENCE AND INCIDENCE OF RHEUMATOID ARTHRITIS 58
• FIGURE 17 PREVALENCE AND INCIDENCE OF OSTEOARTHRITIS 59
• FIGURE 18 PREVALENCE AND INCIDENCE OF OSTEOPOROSIS 60
• FIGURE 19 PREVALENCE AND INCIDENCE OF PSORIATIC ARTHRITIS 61
• FIGURE 20 PREVALENCE AND INCIDENCE OF ANKYLOSING SPONDYLITIS 62
• FIGURE 21 INCIDENSE OF FIBROMYALGIA 63
• FIGURE 22 PREVALENCE AND INCIDENCE OF TENDINITIS AND CARPEL TUNNEL SYNDROME 64
• FIGURE 23 PREVALENCE AND INCIDENCE OF BONE FRACTURES 65
• FIGURE 24 PREVALENCE AND INCIDENCE OF OSTEOMALACIA AND OSTEOPENIA 66
• FIGURE 25 PREVALENCE AND INCIDENCE OF GOUT 67
• FIGURE 26 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MUSCULOSKETAL (MSK) DISEASE MANAGEMENT MARKET 73
• FIGURE 27 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2022 83
• FIGURE 28 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2023-2030 (USD MILLION) 84
• FIGURE 29 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, CAGR (2023-2030) 84
• FIGURE 30 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, LIFELINE CURVE 85
• FIGURE 31 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2022 95
• FIGURE 32 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION) 96
• FIGURE 33 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, CAGR (2023-2030) 96
• FIGURE 34 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, LIFELINE CURVE 97
• FIGURE 35 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2022 101
• FIGURE 36 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2023-2030 (USD MILLION) 102
• FIGURE 37 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, CAGR (2023-2030) 102
• FIGURE 38 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, LIFELINE CURVE 103
• FIGURE 39 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2022 112
• FIGURE 40 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2023-2030 (USD MILLION) 113
• FIGURE 41 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, CAGR (2023-2030) 113
• FIGURE 42 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, LIFELINE CURVE 114
• FIGURE 43 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2022 122
• FIGURE 44 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 123
• FIGURE 45 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, CAGR (2023-2030) 123
• FIGURE 46 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, LIFELINE CURVE 124
• FIGURE 47 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2022 135
• FIGURE 48 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2023-2030 (USD MILLION) 136
• FIGURE 49 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, CAGR (2023-2030) 136
• FIGURE 50 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, LIFELINE CURVE 137
• FIGURE 51 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2022 142
• FIGURE 52 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2023-2030 (USD MILLION) 143
• FIGURE 53 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, CAGR (2023-2030) 143
• FIGURE 54 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, LIFELINE CURVE 144
• FIGURE 55 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022) 154
• FIGURE 56 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022) 156
• FIGURE 57 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030) 156
• FIGURE 58 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030) 157
• FIGURE 59 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030) 157
• FIGURE 60 NORTH AMERICA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%) 192